Skip to main content
SpringerLink
Log in

Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation

  • Protocol
  • First Online:
Oncolytic Viruses

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2058))

Abstract

Newcastle disease virus (NDV) is an avian paramyxovirus that has been extensively studied as an oncolytic agent, in addition to being an economically important pathogen in the poultry industry. The establishment of a reverse genetics system for this virus has enabled the development of genetically modified recombinant NDV viruses with improved oncolytic and immunotherapeutic properties. In this chapter, we describe the materials and methods involved in the in vitro cloning and rescue of NDV expressing murine 4-1BBL as well as the in vivo evaluation of NDV expressing 4-1BBL in a B16-F10 murine melanoma model.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lancaster JE (2007) A history of Newcastle disease with comments on its economic effects. Worlds Poult Sci J 32(2):167–175. https://doi.org/10.1079/WPS19760001

    Article  Google Scholar 

  2. Lamb RA, Parks GD (2007) Paramyxoviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM (eds) Fields Virology, 5th edition, vol 1. Lippincott Williams and Wilkins, Philadelphia, PA, pp 1449–1496.

    Google Scholar 

  3. Nagai Y, Hamaguchi M, Toyoda T (1989) Molecular biology of Newcastle disease virus. Prog Vet Microbiol Immunol 5:16–64

    CAS  PubMed  Google Scholar 

  4. Krishnamurthy S, Samal SK (1998) Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J Gen Virol 79(Pt 10):2419–2424. https://doi.org/10.1099/0022-1317-79-10-2419

    Article  CAS  PubMed  Google Scholar 

  5. Panda A, Huang Z, Elankumaran S, Rockemann DD, Samal SK (2004) Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog 36(1):1–10

    Article  CAS  PubMed  Google Scholar 

  6. Bukreyev A, Huang Z, Yang L, Elankumaran S, St. Claire M, Murphy BR, Samal SK, Collins PL (2005) Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 79(21):13275

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kim SH, Samal SK (2016) Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. Viruses 8(7):183. https://doi.org/10.3390/v8070183

    Article  CAS  PubMed Central  Google Scholar 

  8. Flanagan AD, Love R, Tesar W (1955) Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. Proc Soc Exp Biol Med 90(1):82–86

    Article  CAS  PubMed  Google Scholar 

  9. Sinkovics J (1957) Studies on the biological characteristics of the Newcastle disease virus (NDV) adapted to the brain of newborne mice. Arch Gesamte Virusforsch 7(4):403–411

    Article  CAS  PubMed  Google Scholar 

  10. Eaton MD, Levinthal JD, Scala AR (1967) Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma. J Natl Cancer Inst 39(6):1089–1097

    CAS  PubMed  Google Scholar 

  11. Cassel WA, Garrett RE (1965) Newcastle disease virus as an antineoplastic agent. Cancer 18(7):863–868. https://doi.org/10.1002/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V

    Article  CAS  PubMed  Google Scholar 

  12. Cassel WA, Garrett RE (1966) Tumor immunity after viral oncolysis. J Bacteriol 92(3):792

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Murray DR, Cassel WA, Torbin AH, Olkowski ZL, Moore ME (1977) Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer 40(2):680–686

    Article  CAS  PubMed  Google Scholar 

  14. Cassel WA, Murray DR (1992) A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9(4):169–171

    CAS  PubMed  Google Scholar 

  15. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA (1998) A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4(12):783–794

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kirchner HH, Anton P, Atzpodien J (1995) Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 13(3):171–173

    Article  CAS  PubMed  Google Scholar 

  17. Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, Bodey B, Csatary CM (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17(6):619–627

    CAS  PubMed  Google Scholar 

  18. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B, Csatary CM (2004) MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neuro-Oncol 67(1-2):83–93

    Article  CAS  Google Scholar 

  19. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13(1):221–228. https://doi.org/10.1016/j.ymthe.2005.08.016

    Article  CAS  PubMed  Google Scholar 

  20. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20(9):2251–2266. https://doi.org/10.1200/jco.2002.08.042

    Article  CAS  PubMed  Google Scholar 

  21. Lorence RM, Pecora AL, Major PP, Hotte SJ, Laurie SA, Roberts MS, Groene WS, Bamat MK (2003) Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 5(6):618–624

    CAS  PubMed  Google Scholar 

  22. Schirrmacher V (2016) Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicine 4(3). https://doi.org/10.3390/biomedicines4030016

    Article  PubMed Central  Google Scholar 

  23. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA (1992) Newcastle disease virus selectively kills human tumor cells. J Surg Res 52(5):448–453

    Article  CAS  PubMed  Google Scholar 

  24. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J (1994) Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 9(3):225–235

    Article  CAS  PubMed  Google Scholar 

  25. Sinkovics JG, Horvath JC (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16(1):1–15

    Article  CAS  PubMed  Google Scholar 

  26. Peeters BP, de Leeuw OS, Koch G, Gielkens AL (1999) Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73(6):5001–5009

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Molouki A, Peeters B (2017) Rescue of recombinant Newcastle disease virus: a short history of how it all started. Arch Virol 162(7):1845–1854. https://doi.org/10.1007/s00705-017-3308-2

    Article  CAS  PubMed  Google Scholar 

  28. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martinez-Sobrido L, Woo SL, Garcia-Sastre A (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67(17):8285–8292. https://doi.org/10.1158/0008-5472.can-07-1025

    Article  CAS  PubMed  Google Scholar 

  29. Vigil A, Martinez O, Chua MA, Garcia-Sastre A (2008) Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 16(11):1883–1890. https://doi.org/10.1038/mt.2008.181

    Article  CAS  PubMed  Google Scholar 

  30. Zamarin D, Martinez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, Garcia-Sastre A, Palese P, Fong Y (2009) Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 17(4):697–706. https://doi.org/10.1038/mt.2008.286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y (2010) Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med (Berl) 88(6):589–596. https://doi.org/10.1007/s00109-010-0605-6

    Article  Google Scholar 

  32. Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ (2011) Therapeutic effects of a fusogenic Newcastle disease virus in treating head and neck cancer. Head Neck 33(10):1394–1399. https://doi.org/10.1002/hed.21609

    Article  PubMed  Google Scholar 

  33. Zamarin D, Palese P (2012) Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7(3):347–367. https://doi.org/10.2217/fmb.12.4

    Article  CAS  PubMed  Google Scholar 

  34. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra232. https://doi.org/10.1126/scitranslmed.3008095

    Article  CAS  Google Scholar 

  35. Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D (2018) Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget 9(47):28702–28716. https://doi.org/10.18632/oncotarget.25614

    Article  PubMed  PubMed Central  Google Scholar 

  36. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP (2017) Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 8:14340. https://doi.org/10.1038/ncomms14340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68. https://doi.org/10.1146/annurev.immunol.23.021704.115839

    Article  CAS  PubMed  Google Scholar 

  38. Sznol M, Hodi FS, Margolin DF, McDermott D, Ernstoff JM, Kirkwood JM, Wojtaszek C, Feltquate D, Logan T (2008) Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). Paper presented at the 2008 ASCO Annual Meeting, Chicago, IL

    Google Scholar 

  39. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, Villar E, Garcia-Sastre A, Palese P (2001) Recombinant Newcastle disease virus as a vaccine vector. J Virol 75(23):11868–11873. https://doi.org/10.1128/jvi.75.23.11868-11873.2001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zhao H, Peeters BP (2003) Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol 84(Pt 4):781–788. https://doi.org/10.1099/vir.0.18884-0

    Article  CAS  PubMed  Google Scholar 

  41. Zhao W, Zhang Z, Zsak L, Yu Q (2015) P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression. J Gen Virol 96(Pt 1):40–45. https://doi.org/10.1099/vir.0.068437-0

    Article  CAS  PubMed  Google Scholar 

  42. Marcos F, Ferreira L, Cros J, Park MS, Nakaya T, Garcia-Sastre A, Villar E (2005) Mapping of the RNA promoter of Newcastle disease virus. Virology 331(2):396–406. https://doi.org/10.1016/j.virol.2004.10.040

    Article  CAS  PubMed  Google Scholar 

  43. Beaty SM, Park A, Won ST, Hong P, Lyons M, Vigant F, Freiberg AN, tenOever BR, Duprex WP, Lee B (2017) Efficient and robust Paramyxoviridae reverse genetics systems. mSphere 2(2). https://doi.org/10.1128/mSphere.00376-16

  44. Overwijk WW, Restifo NP (2001) B16 as a mouse model for human melanoma. Curr Protoc Immunol. Chapter 20:Unit 20.1. https://doi.org/10.1002/0471142735.im2001s39

Download references

Acknowledgements

D.Z. is funded by the Liz Tilberis Award from the Ovarian Cancer Research Alliance, and the Department of Defense Ovarian Cancer Research Academy (OC150111). D.Z. is a member of the Parker Institute for Cancer Immunotherapy, which supports the MSKCC Cancer Immunotherapy Program. MSKCC is supported by the NCI Core grant P30 CA008748.

Competing financial interests: D.Z. is an inventor on a patent concerning the uses of recombinant Newcastle Disease Virus for cancer therapy.

Author information

Authors and Affiliations

  1. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Gayathri Vijayakumar

  2. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Gayathri Vijayakumar

  3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dmitriy Zamarin

  4. Department of Medicine, Weil Cornell Medical College, New York, NY, USA

    Dmitriy Zamarin

  5. Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dmitriy Zamarin

Authors
  1. Gayathri Vijayakumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dmitriy Zamarin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dmitriy Zamarin .

Editor information

Editors and Affiliations

  1. Research Group Mechanisms of Oncolytic Immunotherapy, Clinical Cooperation Unit Virotherapy, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), University Hospital Heidelberg, Heidelberg, Germany

    Christine E. Engeland

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Vijayakumar, G., Zamarin, D. (2020). Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. In: Engeland, C. (eds) Oncolytic Viruses. Methods in Molecular Biology, vol 2058. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9794-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9794-7_9

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9793-0

  • Online ISBN: 978-1-4939-9794-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation